Fibrotic valvular heart disease subsequent to bromocriptine treatment.
Ergot alkaloids, such as ergotamine, have been associated with numerous vascular complications and with valvular heart disease. The authors describe a man who developed fibrosis of three heart valves during a 5-year treatment with bromocriptine for Parkinson disease. There were no other plausible causes. To our knowledge, such a side effect has never been described with this drug.
Serratrice
Jacques
J
Service de Médecine Interne, the Service de Cardiologie B, CHU Timone, Marseille Cedex 5, France.
Disdier
Patrick
P
Habib
Gilbert
G
Viallet
François
F
Weiller
Pierre-Jean
PJ
D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D005355:Fibrosis / Q000139:chemically induced* / Q000175:diagnosis; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy
D001971:Bromocriptine